Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024
Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …

News

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024
Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial

Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …

News

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024
Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi

Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …

News

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

June 19, 2024
Research and Development Assembly Biosciences, Hepatology, clinical trial, hepatitis

Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …

News

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024
Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar

June 18, 2024
Sales and Marketing Advanz Pharma, Alvotech, Opthalmology, biosimilar

Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation of AVT06, Alvotech’s proposed biosimilar …

News

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024
Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …

News

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

June 17, 2024
Research and Development Innate Pharma, Oncology, blood cancer, clinical trial

Innate Pharma has announced updated efficacy and safety results from the dose-escalation part of the phase 1/2 study with SAR443579/IPH6101 …

News

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024
Medical Communications CytoSorbents, EU, Haematology, PuriFi, blood pump

CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi haemoperfusion machine in the EU following its approval …

News

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024
Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease

AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …

News

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024
Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …

News

Cara Therapeutics shares data from part a of notalgia paresthetica trial

June 13, 2024
Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus

Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …

News

Tracon shares data from phase 2 trial for glioblastoma treatment

June 12, 2024
Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma

Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …

News

Evotec shares progress in Bristol Myers Squibb neuroscience collaboration

June 12, 2024
Research and Development Evotec, Neurology, bristol myers squibb, neuroscience

Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

FDA accepts Eisai’s Leqembi sBLA for early AD treatment

June 11, 2024
Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …

News

Santhera announces Early Access Program by partner Sperogenix for DMD treatment

June 11, 2024
Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera

Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …

News

Eli Lilly shares results for tirzepatide for MASH resolution

June 10, 2024
Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …

News

GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients

June 10, 2024
Medical Communications FDA, GSK, Immunology, Vaccine

GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) …

News

Nuclera gains £1.14m funding from Innovate UK

June 7, 2024
Research and Development Innovate UK, Nuclera, Pharmacy, grants

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

News
yunus-tug-lnfgdbcajxu-unsplash

FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia

June 7, 2024
Medical Communications FDA, Geron, Haematology, anaemia, mds

Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …

News

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024
Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma

AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …

News

Latest content

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

June 19, 2024

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024